Credit Suisse Group Analysts Give Puma Biotechnology (PBYI) a $147.00 Price Target

Puma Biotechnology (NASDAQ:PBYI) has been given a $147.00 price objective by analysts at Credit Suisse Group in a research report issued on Monday. The brokerage presently has a “buy” rating on the biopharmaceutical company’s stock. Credit Suisse Group’s price target would indicate a potential upside of 56.47% from the stock’s current price.

Several other equities analysts have also recently commented on PBYI. Zacks Investment Research cut Puma Biotechnology from a “hold” rating to a “sell” rating in a report on Monday, January 15th. Citigroup reaffirmed a “buy” rating and issued a $156.00 price target (up previously from $114.00) on shares of Puma Biotechnology in a report on Thursday, October 5th. JPMorgan Chase & Co. reaffirmed a “buy” rating and issued a $131.00 price target on shares of Puma Biotechnology in a report on Wednesday, October 4th. Stifel Nicolaus upped their price target on Puma Biotechnology from $110.00 to $130.00 and gave the company a “buy” rating in a report on Monday, October 2nd. Finally, ValuEngine cut Puma Biotechnology from a “hold” rating to a “sell” rating in a report on Wednesday, January 3rd. Two equities research analysts have rated the stock with a sell rating, one has given a hold rating and nine have given a buy rating to the company. The company has an average rating of “Buy” and an average target price of $131.22.

Puma Biotechnology (PBYI) traded up $2.35 during trading on Monday, reaching $93.95. The company’s stock had a trading volume of 1,010,000 shares, compared to its average volume of 673,625. The firm has a market cap of $3,530.00, a PE ratio of -11.47 and a beta of 0.72. Puma Biotechnology has a 12-month low of $28.35 and a 12-month high of $136.90.

Puma Biotechnology (NASDAQ:PBYI) last posted its quarterly earnings results on Thursday, November 9th. The biopharmaceutical company reported ($2.07) EPS for the quarter, beating the consensus estimate of ($2.50) by $0.43. The firm had revenue of $6.10 million during the quarter, compared to analyst estimates of $3.78 million. During the same period last year, the company earned ($1.11) EPS. equities analysts expect that Puma Biotechnology will post -8.17 earnings per share for the current year.

In other news, insider Charles R. Eyler sold 1,322 shares of the company’s stock in a transaction that occurred on Friday, December 1st. The stock was sold at an average price of $105.46, for a total value of $139,418.12. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Corporate insiders own 21.10% of the company’s stock.

Several hedge funds have recently added to or reduced their stakes in the company. Vanguard Group Inc. grew its stake in shares of Puma Biotechnology by 1.9% in the 2nd quarter. Vanguard Group Inc. now owns 2,474,644 shares of the biopharmaceutical company’s stock valued at $216,284,000 after purchasing an additional 45,735 shares during the period. Janus Henderson Group PLC grew its position in Puma Biotechnology by 1.8% during the 3rd quarter. Janus Henderson Group PLC now owns 1,890,901 shares of the biopharmaceutical company’s stock worth $226,435,000 after acquiring an additional 33,270 shares during the last quarter. BlackRock Inc. grew its position in Puma Biotechnology by 5.0% during the 2nd quarter. BlackRock Inc. now owns 1,830,342 shares of the biopharmaceutical company’s stock worth $159,973,000 after acquiring an additional 86,924 shares during the last quarter. Perceptive Advisors LLC grew its position in Puma Biotechnology by 26.0% during the 3rd quarter. Perceptive Advisors LLC now owns 923,820 shares of the biopharmaceutical company’s stock worth $110,627,000 after acquiring an additional 190,500 shares during the last quarter. Finally, Point72 Asset Management L.P. grew its position in Puma Biotechnology by 265.6% during the 3rd quarter. Point72 Asset Management L.P. now owns 482,200 shares of the biopharmaceutical company’s stock worth $57,743,000 after acquiring an additional 350,300 shares during the last quarter. Institutional investors own 95.86% of the company’s stock.

ILLEGAL ACTIVITY WARNING: This piece of content was first reported by American Banking News and is owned by of American Banking News. If you are reading this piece of content on another domain, it was illegally copied and reposted in violation of United States & international copyright legislation. The correct version of this piece of content can be read at https://www.americanbankingnews.com/2018/01/22/credit-suisse-group-analysts-give-puma-biotechnology-pbyi-a-147-00-price-target.html.

Puma Biotechnology Company Profile

Puma Biotechnology, Inc is a biopharmaceutical company that focuses on the development and commercialization of products for the treatment of cancer. The Company focuses on in-licensing the development and commercialization rights to over three drug candidates, including PB272 (neratinib (oral)), PB272 (neratinib (intravenous)) and PB357.

Analyst Recommendations for Puma Biotechnology (NASDAQ:PBYI)

Leave a Reply